Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 7/20 | 0.67 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.67 |
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157383 | 0.90 | MTNR1B (0.57) | MTNR1BMTNR1ACCR2PLA2G2AKMT2A | |
| SCHEMBL6778354 | 0.88 | MTNR1B (0.66) | MTNR1BMTNR1ACCR2PLA2G2AKMT2A | |
| SCHEMBL13632218 | 0.85 | MTNR1B (0.60) | MTNR1BMTNR1ACCR2PLA2G2AKMT2A | |
| SCHEMBL2157047 | 0.83 | MAPK1 (0.58) | MTNR1BMTNR1ACCR2PLA2G2AKMT2A | |
| SCHEMBL2156559 | 0.82 | MTNR1B (0.49) | MTNR1BMTNR1APLA2G2A | |
| SCHEMBL25136 | 0.82 | MTNR1B (0.60) | MTNR1BMTNR1ACCR2PLA2G2AMAPT | |
| SCHEMBL23282978 | 0.81 | MTNR1B (0.46) | MTNR1BMTNR1ACCR2KMT2AMAPK1 | |
| SCHEMBL6771136 | 0.80 | MTNR1B (0.70) | MTNR1BMTNR1ACCR2PLA2G2APTGDR2 | |
| SCHEMBL25838 | 0.80 | MEN1 (0.51) | MTNR1BMTNR1APLA2G2AKMT2ACYP19A1 | |
| SCHEMBL27795134 | 0.80 | CYP19A1 (0.49) | MTNR1BMTNR1APLA2G2AKMT2ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1950200-B1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor | LILLY CO ELI (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2341045-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor | Eli Lilly and Company (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-1950200-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor | ELI LILLY AND COMPANY (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1202963-B1 | SPLA2 INHIBITORS | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1220839-B1 | HYDROXYFUNCTIONAL AMIDE 1H-INDOLE DERIVATIVES ACTIVE AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1100492-B1 | INDOLE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-05-24 | — | — | EP | disclosed |
| US-7026348-B2 | Indole sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1058547-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING THE PHOSPHOLIPASE INHIBITOR SODIUM 3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-PHENYLMETHYL)-1H-INDOL-4-YL]OXY]ACETATE | SHIONOGI & CO (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-6939890-B2 | Antiinflammatory agents; sepsis shock; rheumatic disorders | ELI LILLY AND COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1084108-A4 | SPLA 2? INHIBITOR COMPOUNDS FOR TREATMENT OF DISEASE | LILLY CO ELI (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-1999024033-A1 | METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1999-05-20 | — | — | WO | disclosed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998047507-A1 | METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998042343-A1 | METHOD FOR TREATMENT OF CHRONIC BRONCHITIS | ELI LILLY AND COMPANY (US) | 1998-10-01 | — | — | WO | disclosed |
| US-5733923-A | SECRETORY PANCREATIC PHOSPHOLIPASE A2 | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5684034-A | INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE | ELI LILLY AND COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| US-5654326-A | SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0675110-A1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |